Bacterial and Fungal Coinfection in Individuals with Coronavirus: A Rapid Review to Support COVID-19 Antimicrobial Prescribing

Clinical Infectious Diseases

Volumn 71, Issue 9, 2020, Pages 2459-2468

  Rawson, Timothy M ^a   Moore, Luke S P ^a,b,c   Zhu, Nina ^a   Ranganathan, Nishanthy ^a,b   Skolimowska, Keira ^a,b   Gilchrist, Mark ^a,b   Satta, Giovanni ^a,b   Cooke, Graham ^a,b   Holmes, Alison ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

antimicrobial resistance; antimicrobial stewardship; SARS CoV 2

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; CASPOFUNGIN; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFOTETAN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; FLUCONAZOLE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MACROLIDE; MEROPENEM; MOXIFLOXACIN; OXACILLIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; FEMALE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; MALE; MIDDLE EAST RESPIRATORY SYNDROME; MIXED INFECTION; MYCOSIS; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SECONDARY ANALYSIS; SEVERE ACUTE RESPIRATORY SYNDROME; SYSTEMATIC REVIEW; ANTIMICROBIAL STEWARDSHIP; DRUG EFFECT; MICROBIOLOGY;

ANTI-INFECTIVE AGENTS; ANTIMICROBIAL STEWARDSHIP; BACTERIAL INFECTIONS; COINFECTION; COVID-19; DRUG RESISTANCE, MICROBIAL; HUMANS; MYCOSES; SARS-COV-2;

EID: 85091924493     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciaa530     Document Type: Article

References (53)

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382:727-33.
2. Zhou F, Yu T, Du R, et al. Articles Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study. Lancet 2020; 6736:1-9.
3. Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: challenges for global health governance. JAMA 2020; 323:709-10.
4. Truog RD, Mitchell C, Daley GQ. The toughest triage - allocating ventilators in a pandemic. N Engl J Med 2020:NEJMp2005689. doi:10.1056/NEJMp2005689
5. Rosenbaum L. Facing Covid-19 in Italy-ethics, logistics, and therapeutics on the epidemic's front line. N Engl J Med 2020; 382:1873-5. doi:10.1056/ NEJMp2005492
6. Hunter DJ. Covid-19 and the stiff upper lip-the pandemic response in the United Kingdom. N Engl J Med 2020; 382:e31.
7. Gautret P, Lagier JC, Parola P, et al. Journal pre-proof hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial. Int J Antimicrob Agents 2020:105949. doi:10.1016/j. ijantimicag.2020.105949
8. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis 2020:ciaa272. doi:10.1093/ cid/ciaa272.
9. Italian Society of Infectious and tropical diseases Lombary Region Section. Vademecum per la cura delle personecon malattia da COVI-19; versione 2.0, 2020. Available at: http://www.simit.org/medias/1569-covid19-vademecum-13-03-202. pdf. Accessed 18 April 2020.
10. Zheng Y, Chen J, Kong D, et al. Pathogenic characteristics of hospitalized severe acute respiratory infections in Shanghai, China, 2015-2017. Chinese J Endem 2019; 40:911-6.
11. Mason JW. Antimicrobials and QT prolongation. J Antimicrob Chemother 2017; 72:1272-4. doi:10.1093/jac/dkw591
12. Holmes AH, Moore LSP, Sundsfjord A, et al. Understanding the mechanisms and drivers of antimicrobial resistance. Lancet 2015; 6736.
13. Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR). Available at: http://www.prisma-statement. org/. Accessed 18 April 2020.
14. Nicholls JM, Poon LL, Lee KC, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003; 361:1773-8.
15. Wang JB, Xu N, Shi HZ, Huang XZ, Lin L. Organism distribution and drug resistance in 7 cases of severe acute respiratory syndrome death patients with secondary bacteria infection. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2003; 15:523-5.
16. Yu N, Li W, Kang Q, et al. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, singlecentre, descriptive study. Lancet Infect Dis 2020; 20:p559-564. doi:10.1016/ S1473-3099(20)30176-6
17. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497-506.
18. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington State. JAMA 2020; 323:1612-4. doi:10.1001/jama.2020.4326
19. Kozak R, Prost K, Yip L, Williams V, Leis JA, Mubareka S. Severity of coronavirus respiratory tract infections in adults admitted to acute care in Toronto, Ontario. J Clin Virol 2020; 126:104338.
20. Chen L, Liu HG, Liu W, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43:E005.
21. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med 2020:NEJMc2010419. doi:10.1056/NEJMc2010419
22. Jung HS, Kang BJ, Ra SW, et al. Elucidation of bacterial pneumonia-causing pathogens in patients with respiratory viral infection. Tuberc Respir Dis (Seoul) 2017;80:358-67.
23. Tan FL, Loo WL, Tan SG, Wong CY, Tan YM. Severe acute respiratory syndrome in surgical patients: a diagnostic dilemma. ANZ J Surg 2005; 75:21-6.
24. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395:507-13.
25. Dong X, Cao Y, Lu X, et al. Eleven faces of coronavirus disease 2019. Allergy 2020. doi:10.1111/all.14289
26. Arabi YM, Deeb AM, Al-Hameed F, et al; Saudi Critical Care Trials Group. Macrolides in critically ill patients with Middle East respiratory syndrome. Int J Infect Dis 2019; 81:184-90.
27. Jang TN, Yeh DY, Shen SH, Huang CH, Jiang JS, Kao SJ. Severe acute respiratory syndrome in Taiwan: analysis of epidemiological characteristics in 29 cases. J Infect 2004; 48:23-31.
28. Yap FH, Gomersall CD, Fung KS, et al. Increase in methicillin-resistant Staphylococcus aureus acquisition rate and change in pathogen pattern associated with an outbreak of severe acute respiratory syndrome. Clin Infect Dis 2004; 39:511-6.
29. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323:1061-9.
30. Shweihat Y, Perry J 3rd, Shah D. Isolated Candida infection of the lung. Respir Med Case Rep 2015; 16:18-9.
31. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region-case series. N Engl J Med 2020. doi:10.1056/NEJMoa2004500
32. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382:1708-20. doi:10.1056/NEJMoa2002032
33. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382:929-6. doi:10.1056/NEJMoa2002032
34. Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. JAMA 2020. doi:10.1001/ jama.2020.6266
35. Liu YC, Liao CH, Chang CF, Chou CC, Lin YR. A locally transmitted case of SARS-CoV-2 infection in Taiwan. N Engl J Med 2020; 382:1070-2.
36. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020. doi:10.1001/jamainternmed.2020.0994
37. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020;323:1488-
38. doi:10.1001/jama.2020.3204
39. Paret M, Lighter J, Pellett Madan R, Raabe VN, Shust GF, Ratner AJ. SARS-CoV-2 infection (COVID-19) in febrile infants without respiratory distress. Clin Infect Dis 2020. doi:10.1093/cid/ciaa452
40. Cao J, Tu WJ, Cheng W, et al. Clinical features and short-term outcomes of 102 patients with corona virus disease 2019 in Wuhan, China. Clin Infect Dis 2020. doi:10.1093/cid/ciaa243
41. Rawson TM, Moore LSP, Castro-Sánchez E, et al. COVID-19 and the potential long term impact on antimicrobial resistance. J Antimicrob Chemother 2020.
42. Meier MA, Branche A, Neeser OL, et al. Procalcitonin-guided antibiotic treatment in patients with positive blood cultures: a patient-level meta-analysis of randomized trials. Clin Infect Dis 2019; 69:388-96.
43. de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 2016; 16:819-27.
44. Rawson TM, Hernandez B, Moore LSP, et al. A real-world evaluation of a Case- Based Reasoning algorithm to support antimicrobial prescribing decisions in acute care. Clin Infect Dis 2020. doi:10.1093/cid/ciaa383.
45. Food and Drug Adminstration. Drug shortages. Available at: https://www. fda.gov/drugs/drug-safety-and-availability/drug-shortages. Accessed 18 April 2020.
46. Victoria Rees. EMA announces measures to manage drug shortages due to COVID-19. Available at: https://www.europeanpharmaceuticalreview.com/ news/115123/ema-announces-measures-to-manage-drug-shortages-as-resultof- covid-19/. Accessed 18 April 2020.
47. Wald-Dickler N, Spellberg B. Short course antibiotic therapy-replacing Constantine units with "shorter is better". Clin Infect Dis 2019; 69:1476-9.
48. Lorgelly PK, Atkinson M, Lakhanpaul M, et al. Oral versus i.v. antibiotics for community-acquired pneumonia in children: a cost-minimisation analysis. Eur Respir J 2010; 35:858-64.
49. Chan R, Hemeryck L, O'Regan M, Clancy L, Feely J. Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open, randomised controlled trial. BMJ 1995; 310:1360-2.
50. Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med 2019; 380:415-24.
51. Li HK, Rombach I, Zambellas R, et al; OVIVA Trial Collaborators. Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med 2019; 380:425-36.
52. Heffernan AJ, Sime FB, Taccone FS, Roberts JA. How to optimize antibiotic pharmacokinetic/ pharmacodynamics for gram-negative infections in critically ill patients. Curr Opin Infect Dis 2018; 31:555-65.
53. Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect Dis Clin North Am 2009; 23:791-815, vii.